South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol (SCCCG-R-ALL)
Sponsor: First Affiliated Hospital of Guangxi Medical University
Listed as NCT05682131, this PHASE4 trial focuses on Arsenic Trioxide and Childhood ALL and remains actively recruiting participants. Sponsored by First Affiliated Hospital of Guangxi Medical University, it has been updated 3 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
3 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Feb 2023 — Jul 2024 [monthly]
Recruiting PHASE4
First recorded
Sep 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First Affiliated Hospital of Guangxi Medical University
- First Affiliated Hospital of Shantou University Medical College
- First Affiliated Hospital, Sun Yat-Sen University
- Guangzhou First People's Hospital
- Hainan People's Hospital
- Huizhou Municipal Central Hospital
- LiuZhou People's Hospital
- Second Xiangya Hospital of Central South University
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- The First Affiliated Hospital of Guangzhou Medical University
- Third Affiliated Hospital, Sun Yat-Sen University
- Zhongshan Bo Ai Hospital
- Zhongshan People's Hospital, Guangdong, China
- Zhujiang Hospital
For direct contact, visit the study record on ClinicalTrials.gov .